The Neural Network of Global Safety Reporting

In the rapidly evolving landscape of pharmacovigilance, ensuring drug safety and efficacy is paramount. Traditional methods of adverse event detection and reporting are often time-consuming and resource-intensive.^[1] Enter neural networks, a powerful subset of artificial intelligence (AI), poised to revolutionize global safety reporting.^[2]

Ichelon Pharma this blog post will explore the transformative potential of neural networks in pharmacovigilance, demonstrating how they can enhance the speed, accuracy, and efficiency of drug safety monitoring.

Understanding Neural Networks

Neural networks are computational models inspired by the structure and function of the human brain. They consist of interconnected nodes (neurons) organized in layers, which process and transmit information.^[3] The key components of a neural network include:

• Input Layer: Receives the initial data.
• Hidden Layers: Perform complex computations on the input data.
• Output Layer: Produces the final result.
• Weights and Biases: Adjustable parameters that determine the strength of connections between neurons. These are ‘learned’ during the training process.

Neural networks learn from data through a process called training. During training, the network adjusts its weights and biases to minimize the difference between its predictions and the actual outcomes. This iterative process enables the network to identify patterns and make accurate predictions on new, unseen data. ^[4]

Key Benefits of Neural Networks ^[5,6]

Applications of Neural Networks

1. Adverse Event Detection and Classification ^[7-9]

Neural networks revolutionize how we identify and categorize adverse events, transforming mountains of data into actionable safety intelligence.

• Automated Signal Detection

Neural networks analyze vast volumes of safety data from multiple sources simultaneously, identifying patterns that would be impossible for humans to detect manually. These systems can process millions of reports across global databases, spotting emerging safety signals in real-time

a. Key Capability: Processes 10,000+ reports per hour with 95% accuracy in signal identification

b. Impact: Detects signals 3-6 months earlier than traditional methods

• Text Mining with NLP

Natural Language Processing models extract structured adverse event information from unstructured text sources, including medical literature, clinical narratives, social media posts, and patient forums. These systems understand medical terminology, context, and relationships between drugs and events.

• Deep Learning Classification

Advanced deep learning models automatically categorize adverse events across multiple dimensions, providing consistent and accurate classification at scale

2. Case Processing and Triage ^[11,12]

AI-powered case processing systems handle the entire lifecycle of safety reports, from intake to prioritization, dramatically reducing processing time and improving accuracy.

• Automated Case Intake

Neural networks automatically process incoming safety reports from multiple channels including emails, web forms, phone transcripts, faxes, and regulatory databases. The system extracts key information, validates data quality, and creates standardized case records.

Processing Speed: Reduces case intake time from 45 minutes to under 2 minutes per case

• Intelligent Prioritization

Machine learning models assess case urgency based on multiple factors including severity, causality likelihood, regulatory deadlines, and patient outcome. High-priority cases are immediately routed to senior reviewers while routine cases follow standard workflows.

• Duplicate Detection

Advanced machine learning algorithms identify duplicate reports across different databases, preventing redundant processing and ensuring accurate safety signal counts. The system uses fuzzy matching and similarity scoring to catch duplicates even when data formats differ.

Duplicate Detection Criteria

• Patient demographics match (name, DOB, gender)
• Same suspect medication
• Similar adverse event description
• Overlapping event dates

3. Automated Medical Coding ^[13-15]

AI-powered coding systems automatically assign standardized medical codes to adverse events and medications, ensuring consistency and compliance with international standards.

• MedDRA Coding (Medical Dictionary for Regulatory Activities)

Neural networks automatically assign MedDRA terms to adverse events, navigating the complex hierarchical structure of over 75,000 terms. The system understands medical terminology, synonyms, and contextual usage to select the most appropriate preferred terms (PTs) and lower-level terms (LLTs).

• WHO-DD Coding (WHO Drug Dictionary)

AI systems automatically code medications using the WHO Drug Dictionary, handling brand names, generic names, different formulations, and international naming variations. The system resolves ambiguities and maps drugs to their active ingredients and therapeutic classifications.

• Drug Coding Process

Example: “Tylenol 500mg” → WHO Drug Code: N02BE01 | Preferred Term: Paracetamol

4. AI-Powered Narrative Generation ^[16,17]

Advanced language models generate and enhance case narratives, ensuring completeness, consistency, and regulatory compliance while maintaining medical accuracy.

• Automated Narrative Creation

Neural networks transform structured data fields into coherent, medically accurate narratives that meet regulatory requirements. The system generates clear, comprehensive case summaries from patient demographics, medical history, adverse event details, and concomitant medications.

• Automated Quality Checks

AI systems continuously monitor narrative quality, checking for completeness, consistency, medical accuracy, and regulatory compliance. The system flags issues and suggests improvements in real-time.

AI-Powered Pharmacovigilance Workflow ^[1,7,12]

From data collection to regulatory action, neural networks streamline every step with continuous learning

Benefits & Impact ^[2,5,7]

• Speed & Efficiency: Reduce case processing time by up to 90%, allowing safety teams to focus on critical analysis and decision-making.
• Enhanced Accuracy: Minimize human error and improve consistency in adverse event classification and causality assessment.
• Global Scale: Process reports from multiple countries and languages simultaneously, ensuring comprehensive global surveillance.
• Predictive Capabilities: Identify emerging safety concerns before they become widespread, potentially saving lives through early intervention.

Challenges & Considerations^[2,5,7]

• Data Quality: Neural networks require large, high-quality datasets for training, which can be challenging in pharmacovigilance.
• Regulatory Compliance: Ensuring AI systems meet strict regulatory requirements for transparency and validation.
• Interpretability: Making “black box” neural network decisions transparent and explainable to regulators.
• Human Oversight: Balancing automation with the need for expert pharmacovigilance professional review.

Conclusion

Neural networks are transforming pharmacovigilance from a reactive discipline to a proactive science. As these technologies mature, we can expect even more sophisticated applications, including real-time safety monitoring, personalized risk assessment, and integration with electronic health records.

The key to success lies in thoughtful implementation that combines the power of AI with the irreplaceable expertise of pharmacovigilance professionals, ensuring patient safety remains at the heart of pharmaceutical development and post-market surveillance.

References

1. Algarvio RC, Conceição J, Rodrigues PP, Ribeiro I, Ferreira-da-Silva R. Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool. Int J Clin Pharm. 2025;47(4):932-944. doi:10.1007/s11096-025-01975-3
2. Desai MK. Artificial intelligence in pharmacovigilance – Opportunities and challenges. Perspect Clin Res. 2024;15(3):116-121. doi:10.4103/picr.picr_290_23
3. Pour Haji Kazem AA. Neural networks. In: Decision-Making Models. Elsevier; 2024:3-8. doi:10.1016/B978-0-443-16147-6.00017-7
4. Kriegeskorte N, Golan T. Neural network models and deep learning. Curr Biol CB. 2019;29(7):R231-R236. doi:10.1016/j.cub.2019.02.034
5. Sheikhtaheri A, Sadoughi F, Hashemi Dehaghi Z. Developing and Using Expert Systems and Neural Networks in Medicine: A Review on Benefits and Challenges. J Med Syst. 2014;38(9):110. doi:10.1007/s10916-014-0110-5
6. Forsström JJ, Dalton KJ. Artificial neural networks for decision support in clinical medicine. Ann Med. 1995;27(5):509-517. doi:10.3109/07853899509002462
7. Nagar A, Gobburu J, Chakravarty A. Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration. Ther Adv Drug Saf. 2025;16:20420986251361435. doi:10.1177/20420986251361435
8. Kitzman DW. A Sister’s Sacrifice. J Am Geriatr Soc. 2019;67(3):618-619. doi:10.1111/jgs.15695
9. Dandala B, Joopudi V, Devarakonda M. Adverse Drug Events Detection in Clinical Notes by Jointly Modeling Entities and Relations Using Neural Networks. Drug Saf. 2019;42(1):135-146. doi:10.1007/s40264-018-0764-x
10. Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing. Clin Pharmacol Ther. 2019;105(4):954-961. doi:10.1002/cpt.1255
11. Routray R, Tetarenko N, Abu-Assal C, et al. Application of Augmented Intelligence for Pharmacovigilance Case Seriousness Determination. Drug Saf. 2020;43(1):57-66. doi:10.1007/s40264-019-00869-4
12. Salas M, Petracek J, Yalamanchili P, et al. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature. Pharm Med. 2022;36(5):295-306. doi:10.1007/s40290-022-00441-z
13. Mousavi Baigi SF, Sarbaz M, Darroudi A, Kemmak FD, Aval RN, Kimiafar K. Artificial Intelligence-based Automated International Classification of Diseases Coding: A Systematic Review. J Med Signals Sens. 2025;15:22. doi:10.4103/jmss.jmss_76_24
14. Ly T, Pamer C, Dang O, et al. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology. J Biomed Inform. 2018;83:73-86. doi:10.1016/j.jbi.2018.05.019
15. Lagerlund O, Strese S, Fladvad M, Lindquist M. WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information. Ther Innov Regul Sci. 2020;54(5):1116-1122. doi:10.1007/s43441-020-00130-6
16. Zitu MM, Owen D, Manne A, Wei P, Li L. Large Language Models for Adverse Drug Events: A Clinical Perspective. J Clin Med. 2025;14(15):5490. doi:10.3390/jcm14155490
17. Buess L, Keicher M, Navab N, Maier A, Arasteh ST. From large language models to multimodal AI: A scoping review on the potential of generative AI in medicine. Biomed Eng Lett. 2025;15(5):845-863. doi:10.1007/s13534-025-00497-1